Novartis' Rhapsido shows strong results as first targeted therapy for chronic inducible urticaria in Phase III trial

Novartis announced that its drug Rhapsido (remibrutinib) demonstrated significant symptom control in patients with chronic inducible urticaria (CIndU) across three common subtypes in the global Phase III RemIND trial. The drug showed twice the complete response rate compared to placebo, with early and sustained relief and a favorable safety profile. Rhapsido is under FDA review for the symptomatic dermographism subtype and is already approved for chronic spontaneous urticaria in several regions. This marks a major advancement as no targeted therapies currently exist for CIndU, affecting an estimated 29 million people worldwide.